Ensol Biosciences has pinpointed a pH-driven dual-target action for its oral obesity drug H1K, reigniting global licensing talks and setting the stage for a possible trillion-won deal.
Big-ticket partnerships unravel and safety issues freeze progress as leaders at the 2026 Cell and Gene Meeting on the Mesa shift from custom therapies to platforms built for scale and wider reach.
NCCN's new 10−6 sensitivity benchmark for minimal residual disease in multiple myeloma is shaking up diagnostics, driving labs to overhaul their molecular testing and sparking a scramble among industry players.
Wistar Institute researchers have shown that rewiring myeloid cells and activating T cells together can sharply extend survival in glioblastoma models, breaking through a cancer long known for resisting treatment.
GenoMethods explains biotechnology from method to medicine to market, connecting scientific evidence, clinical development, companies and the technologies shaping future health.
